IL186430A0 - Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications - Google Patents

Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications

Info

Publication number
IL186430A0
IL186430A0 IL186430A IL18643007A IL186430A0 IL 186430 A0 IL186430 A0 IL 186430A0 IL 186430 A IL186430 A IL 186430A IL 18643007 A IL18643007 A IL 18643007A IL 186430 A0 IL186430 A0 IL 186430A0
Authority
IL
Israel
Prior art keywords
tetrahydrothiopyrano
related applications
cross reference
modulators cross
cannabinoid modulators
Prior art date
Application number
IL186430A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL186430A0 publication Critical patent/IL186430A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL186430A 2005-03-31 2007-10-07 Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications IL186430A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689805P 2005-03-31 2005-03-31
PCT/US2006/009424 WO2006107561A1 (en) 2005-03-31 2006-03-16 Tetrahydrothiopyrano pyrazole cannabinoid modulators

Publications (1)

Publication Number Publication Date
IL186430A0 true IL186430A0 (en) 2008-01-20

Family

ID=36587178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186430A IL186430A0 (en) 2005-03-31 2007-10-07 Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications

Country Status (18)

Country Link
US (2) US20060223798A1 (enExample)
EP (1) EP1863479B1 (enExample)
JP (1) JP5127697B2 (enExample)
KR (1) KR20080004559A (enExample)
CN (1) CN101189007A (enExample)
AT (1) ATE416768T1 (enExample)
AU (1) AU2006232945B2 (enExample)
BR (1) BRPI0609790A2 (enExample)
CA (1) CA2603104A1 (enExample)
CO (1) CO6321135A2 (enExample)
CR (1) CR9479A (enExample)
DE (1) DE602006004197D1 (enExample)
EA (1) EA200702130A1 (enExample)
IL (1) IL186430A0 (enExample)
MX (1) MX2007012233A (enExample)
NO (1) NO20075463L (enExample)
WO (1) WO2006107561A1 (enExample)
ZA (1) ZA200709342B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863903B (zh) * 2010-06-08 2014-03-12 沈阳药科大学 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
JP5127697B2 (ja) 2013-01-23
US20060223798A1 (en) 2006-10-05
WO2006107561A1 (en) 2006-10-12
KR20080004559A (ko) 2008-01-09
MX2007012233A (es) 2008-03-18
ATE416768T1 (de) 2008-12-15
US20080085899A1 (en) 2008-04-10
DE602006004197D1 (de) 2009-01-22
AU2006232945A1 (en) 2006-10-12
NO20075463L (no) 2007-12-21
BRPI0609790A2 (pt) 2010-04-27
CO6321135A2 (es) 2011-09-20
CN101189007A (zh) 2008-05-28
EP1863479B1 (en) 2008-12-10
CA2603104A1 (en) 2006-10-12
EP1863479A1 (en) 2007-12-12
US7524964B2 (en) 2009-04-28
JP2008535829A (ja) 2008-09-04
EA200702130A1 (ru) 2008-04-28
AU2006232945B2 (en) 2012-02-23
CR9479A (es) 2008-09-09
ZA200709342B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
IL190348A0 (en) Hexahydro cyclooctyl pyrazole cannabinoid modulators
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008118141A3 (en) Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
TW200604179A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NO20082505L (no) Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer
WO2009023653A3 (en) Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
BRPI0517378A (pt) moduladores de tetraidro piridinil pirazol canabinóide
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2008115705A3 (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
ZA200803532B (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
WO2008087329A3 (fr) Nouveau médicament pour le traitement d'un cancer gastrique
IL186430A0 (en) Tetrahydrothiopyrano pyrazole cannabinoid modulators cross reference to related applications
MX2009010159A (es) Moduladores de cannabinoides hexahidro-ciclooctil pirazol.
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
MX2010003926A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
UA84572C2 (en) N-(morpholylcarbonylaminomethyl)bicyclo[2.2.1]hept-5-en-endo,endo-2,3-dicarboximide that have tranquilizing, anticonvulsant and analgesic action